| Project/Area Number |
26860611
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Respiratory organ internal medicine
|
|---|
| Research Institution | Sapporo Medical University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
MOTOKO TAKAHASHI 札幌医科大学, 医学部, 准教授 (00303941)
|
|---|
| Project Period (FY) |
2014-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2015: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | 肺サーファクタント蛋白質 / EGFR / 肺がん / 肺サーファクタント / SP-A / SP-D |
|---|
| Outline of Final Research Achievements |
Our previous study has indicated that SP-D suppresses EGF signaling by interfering with the ligand-binding to EGFR. SP-D directly binds to the N-glycans of EGFR by lectin activity. In this study, we indicated that SP-A also downregulated EGF signaling by inhibiting ligand-binding to EGFR. In addition, we found that SP-A directly bound to EGFR, but not via N-glycans. Elucidating the antitumor effects of SP-A and SP-D may provide important clues for establishing new therapeutic strategies for lung cancer.
|
